These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 25016390)

  • 1. Deep sequencing of hepatitis C virus hypervariable region 1 reveals no correlation between genetic heterogeneity and antiviral treatment outcome.
    Cortés KC; Zagordi O; Perlejewski K; Laskus T; Maroszek K; Bukowska-Ośko I; Pawełczyk A; Płoski R; Berak H; Horban A; Radkowski M
    BMC Infect Dis; 2014 Jul; 14():389. PubMed ID: 25016390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy.
    Sandres K; Dubois M; Pasquier C; Payen JL; Alric L; Duffaut M; Vinel JP; Pascal JP; Puel J; Izopet J
    J Virol; 2000 Jan; 74(2):661-8. PubMed ID: 10623727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C.
    Pawlotsky JM; Pellerin M; Bouvier M; Roudot-Thoraval F; Germanidis G; Bastie A; Darthuy F; Rémiré J; Soussy CJ; Dhumeaux D
    J Med Virol; 1998 Apr; 54(4):256-64. PubMed ID: 9557291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection.
    Chambers TJ; Fan X; Droll DA; Hembrador E; Slater T; Nickells MW; Dustin LB; Dibisceglie AM
    J Virol; 2005 Mar; 79(5):3071-83. PubMed ID: 15709027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy.
    Sarrazin C; Bruckner M; Herrmann E; Rüster B; Bruch K; Roth WK; Zeuzem S
    Virology; 2001 Oct; 289(1):150-63. PubMed ID: 11601926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
    Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
    J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C.
    Gerotto M; Sullivan DG; Polyak SJ; Chemello L; Cavalletto L; Pontisso P; Alberti A; Gretch DR
    J Virol; 1999 Sep; 73(9):7241-7. PubMed ID: 10438811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.
    Bolcic F; Sede M; Moretti F; Westergaard G; Vazquez M; Laufer N; Quarleri J
    Arch Virol; 2012 Apr; 157(4):703-11. PubMed ID: 22270759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing.
    Nasu A; Marusawa H; Ueda Y; Nishijima N; Takahashi K; Osaki Y; Yamashita Y; Inokuma T; Tamada T; Fujiwara T; Sato F; Shimizu K; Chiba T
    PLoS One; 2011; 6(9):e24907. PubMed ID: 21966381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of hepatitis C Virus genotype 3a hypervariable region 1 in patients achieved rapid virological response to alpha interferon and ribavirin combination therapy.
    Akram M; Idrees M; Hussain A; Afzal S; Ilyas M; Zafar S; Aftab M; Badar S; Khubaib B
    Virol J; 2011 May; 8():253. PubMed ID: 21605410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in different regions of the genome of hepatitis C virus genotype 1b and association with response to interferon therapy.
    Zhang L; Han F; Zhang D; Dou XG
    Int J Mol Med; 2012 Dec; 30(6):1438-42. PubMed ID: 23064792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy.
    Pawlotsky JM; Germanidis G; Frainais PO; Bouvier M; Soulier A; Pellerin M; Dhumeaux D
    J Virol; 1999 Aug; 73(8):6490-9. PubMed ID: 10400744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus quasispecies in chronically infected children subjected to interferon-ribavirin therapy.
    Figlerowicz M; Jackowiak P; Formanowicz P; Kędziora P; Alejska M; Malinowska N; Błażewicz J; Figlerowicz M
    Arch Virol; 2010 Dec; 155(12):1977-87. PubMed ID: 20842394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of 5'UTR and HVR1 of hepatitis c virus (HCV) in serum and peripheral blood mononuclear cells in the early phase of interferon and ribavirin treatment].
    Cortés KC; Ośko I; Pawełczyk A; Berak H; Fic M; Horban A; Radkowski M
    Przegl Epidemiol; 2011; 65(2):319-24. PubMed ID: 21913483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1.
    Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Hara T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2013 Jun; 85(6):1028-36. PubMed ID: 23588728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a.
    Moreau I; Levis J; Crosbie O; Kenny-Walsh E; Fanning LJ
    Virol J; 2008 Jul; 5():78. PubMed ID: 18613968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection.
    Murphy MD; Rosen HR; Marousek GI; Chou S
    Dig Dis Sci; 2002 Jun; 47(6):1195-205. PubMed ID: 12064791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amino acid sequence analysis in patients with chronic HCV genotype 1b infection during pegylated interferon-α2a and ribavirin therapy.
    Fu JJ; Kong WJ; Jiang D; Pan XC; Wei L
    Antivir Ther; 2014; 19(7):661-8. PubMed ID: 24584067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of hepatitis C virus quasispecies heterogeneity by interferon-alpha and ribavirin therapy.
    González-Peralta RP; Liu WZ; Davis GL; Qian KP; Lau JY
    J Viral Hepat; 1997 Mar; 4(2):99-106. PubMed ID: 9097265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic distance and heterogenecity between quasispecies is a critical predictor to IFN response in Egyptian patients with HCV genotype-4.
    Zekri AR; El-Din HM; Bahnassy AA; Khaled MM; Omar A; Fouad I; El-Hefnewi M; Thakeb F; El-Awady M
    Virol J; 2007 Feb; 4():16. PubMed ID: 17300723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.